Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2008

Teva Plans to Acquire CoGenesys for $400M to Advance in the Biogenerics Field

  • Teva Pharmaceutical agreed to acquire CoGenesys for $400 million cash. Teva says that the purchase is an important springboard in the company’s efforts to become a leading player in the biogenerics market.

    “Biopharmaceuticals will be a long-term growth driver for Teva,” remarks Shlomo Yanai, Teva’s president and CEO. “CoGenesys’ acquisition reflects our commitment to capture the significant long-term prospects we believe the biogenerics market will offer.

    “CoGenesys’ breadth of technologies and the depth of their team and pipeline complement Teva’s large-scale operations, extensive resources, and its proven expertise in bringing drugs to market,” Yanai continues. “This combination will enable us to realize our vision of delivering high-quality, affordable biopharmaceuticals worldwide.”

    The transaction is expected to close during the first half of 2008.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »